Work

Updated results from the frailty-stratified, randomised controlled bayesian adaptive trial of bortezomib versus lenalidomide in transplant ineligible myeloma (TI NDMM) – the FRAIL-m study (AMaRC 19-01; ALLG MM22)

Year: 2025

Type: conference-abstract

Source: Blood

DOI: 10.1182/blood-2025-5842

Authors: Sueh-Li Lim, John Reynolds, Lucy Pemberton, Tricia Wright, Sophie Lee, Peter Mollee, Anita C. Shetty, Yu Jin Kim, Weston Helen, Byard Nina, Khoa Le, Zoe McQuilten, Hang Quach, Andrew Spencer

Institutions: The Alfred Hospital, Alfred Health, Monash University, Dunedin Public Hospital, Latrobe Regional Hospital, Western Health, Princess Alexandra Hospital, Nepean Hospital, Sunshine Coast University Hospital, The University of Melbourne, St Vincent's Hospital Melbourne

Language: English

Topic: Multiple Myeloma Research and Treatments

Subfield: Hematology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4417002290

Cites:

Cited by:

Related to: